80_FR_12202 80 FR 12158 - Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting

80 FR 12158 - Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting

DEPARTMENT OF DEFENSE
Office of the Secretary

Federal Register Volume 80, Issue 44 (March 6, 2015)

Page Range12158-12158
FR Document2015-05205

The Department of Defense is publishing this notice to announce a Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel).

Federal Register, Volume 80 Issue 44 (Friday, March 6, 2015) 
[Federal Register Volume 80, Number 44 (Friday, March 6, 2015)]
[Notices]
[Page 12158]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-05205]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense is publishing this notice to 
announce a Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel).

DATES: Thursday, March 26, 2015, from 9 a.m. to 1 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Mr. William H. Blanche, Alternate DFO, 
Uniform Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, 
Suite 5101, Falls Church, VA 22042-5101. Telephone: (703) 681-2890. 
Fax: (703) 681-1940. Email Address: Baprequests@dha.mil.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act of 1972 (title 5, 
United States Code (U.S.C.), Appendix, as amended) and the Government 
in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended).
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of Defense Health Agency, by the 
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.

Meeting Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Public Citizen Comments
4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
a. Pulmonary Artery Hypertension
b. Transmucosal Immediate Release Fentanyl Products
c. Oral Oncology Agents--Prostate I & II
5. Designated Newly Approved Drugs in Already-Reviewed Classes
6. Pertinent Utilization Management Issues
7. Panel Discussions and Vote
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 8:30 a.m. to 9 a.m. to 
discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (DFO). The DFO's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database at http://facadatabase.gov/.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than 5 business days prior 
to the meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1 hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation.
    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: March 3, 2015.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2015-05205 Filed 3-5-15; 8:45 am]
 BILLING CODE 5001-06-P

12158 Federal Register / Vol. 80, No. 44 / Friday, March 6, 2015 / Notices categories for which FPI’s share of the SUMMARY: The Department of Defense is Pursuant to 41 CFR 102–3.160, the DOD market is greater than five percent publishing this notice to announce a Administrative Work Meeting will be based on Fiscal Year 2014 data from the Federal Advisory Committee meeting of closed to the public. Federal Procurement Data System. The the Uniform Formulary Beneficiary Written Statements: Pursuant to 41 product categories to be competed Advisory Panel (hereafter referred to as CFR 102–3.140, the public or interested effective March 29, 2015, are the the Panel). organizations may submit written following: DATES: Thursday, March 26, 2015, from statements to the membership of the • 3990 (Miscellaneous Materials 9 a.m. to 1 p.m. Panel at any time or in response to the Handling Equipment) ADDRESSES: Naval Heritage Center stated agenda of a planned meeting. • 5210 (Measuring Tools, Craftsmen’s) Theater, 701 Pennsylvania Avenue NW., Written statements should be submitted • 7110 (Office Furniture) Washington, DC 20004. to the Panel’s Designated Federal Officer • 7125 (Cabinets, Lockers, Bins and (DFO). The DFO’s contact information FOR FURTHER INFORMATION CONTACT: Mr. Shelving) can be obtained from the General • 7230 (Draperies, Awnings, and William H. Blanche, Alternate DFO, Uniform Formulary Beneficiary Services Administration’s Federal Shades) Advisory Committee Act Database at • 8405 (Outerwear, Men’s) Advisory Panel, 7700 Arlington Boulevard, Suite 5101, Falls Church, VA http://facadatabase.gov/. • 8410 (Outerwear, Women’s) • 8415 (Clothing, Special Purpose) 22042–5101. Telephone: (703) 681– Written statements that do not pertain 2890. Fax: (703) 681–1940. Email to the scheduled meeting of the Panel The DPAP memorandum with the Address: Baprequests@dha.mil. may be submitted at any time. However, current list of product categories for which FPI has a significant market share SUPPLEMENTARY INFORMATION: This if individual comments pertain to a is posted at: http://www.acq.osd.mil/ meeting is being held under the specific topic being discussed at a dpap/policy/policyvault/USA001110- provisions of the Federal Advisory planned meeting, then these statements 15-DPAP.pdf. Committee Act of 1972 (title 5, United must be submitted no later than 5 The statute as implemented also States Code (U.S.C.), Appendix, as business days prior to the meeting in requires DoD to— amended) and the Government in the question. The DFO will review all (1) Include FPI in the solicitation Sunshine Act of 1976 (5 U.S.C. 552b, as submitted written statements and process for these items; a timely offer amended). provide copies to all the committee from FPI must be considered; and award Purpose of Meeting: The Panel will members. procedures must be followed in review and comment on Public Comments: In addition to accordance with existing policy at recommendations made to the Director written statements, the Panel will set Federal Acquisition Regulation (FAR) of Defense Health Agency, by the aside 1 hour for individuals or 8.602(a)(4)(ii) through (v); Pharmacy and Therapeutics Committee, interested groups to address the Panel. (2) Continue to be make acquisitions, regarding the Uniform Formulary. To ensure consideration of their in accordance with FAR Subpart 8.6, for Meeting Agenda comments, individuals and interested items from product categories for which groups should submit written FPI does not have a significant market 1. Sign-In statements as outlined in this notice; but share. FAR 8.602 requires agencies to 2. Welcome and Opening Remarks if they still want to address the Panel, conduct market research and make a 3. Public Citizen Comments then they will be afforded the written comparability determination, at 4. Scheduled Therapeutic Class Reviews opportunity to register to address the the discretion of the contracting officer. (Comments will follow each agenda Panel. The Panel’s DFO will have a Competitive (or fair opportunity) item) a. Pulmonary Artery Hypertension ‘‘Sign-Up Roster’’ available at the Panel procedures are appropriate if the FPI meeting for registration on a first-come, b. Transmucosal Immediate Release product is not comparable in terms of first-serve basis. Those wishing to Fentanyl Products price, quality, or time of delivery; and address the Panel will be given no more c. Oral Oncology Agents—Prostate I & II (3) Section 827 allows modification of than 5 minutes to present their 5. Designated Newly Approved Drugs in the published list if DoD subsequently comments, and at the end of the 1 hour Already-Reviewed Classes determines that new data requires time period, no further public 6. Pertinent Utilization Management adding or omitting a product category comments will be accepted. Anyone Issues from the list. 7. Panel Discussions and Vote who signs-up to address the Panel, but Manuel Quinones, Meeting Accessibility: Pursuant to 5 is unable to do so due to the time U.S.C. 552b, as amended, and 41 Code limitation, may submit their comments Editor, Defense Acquisition Regulations Council. of Federal Regulations (CFR) 102–3.140 in writing; however, they must through 102–3.165, and the availability understand that their written comments [FR Doc. 2015–05270 Filed 3–5–15; 8:45 am] of space, this meeting is open to the may not be reviewed prior to the Panel’s BILLING CODE 5001–06–P public. Seating is limited and will be deliberation. provided only to the first 220 people To ensure timeliness of comments for DEPARTMENT OF DEFENSE signing-in. All persons must sign-in the official record, the Panel encourages legibly. that individuals and interested groups Office of the Secretary Administrative Work Meeting: Prior to consider submitting written statements mstockstill on DSK4VPTVN1PROD with NOTICES the public meeting, the Panel will instead of addressing the Panel. Uniform Formulary Beneficiary conduct an Administrative Work Advisory Panel; Notice of Federal Dated: March 3, 2015. Meeting from 8:30 a.m. to 9 a.m. to Advisory Committee Meeting discuss administrative matters of the Aaron Siegel, Panel. The Administrative Work Alternate OSD Federal Register Liaison AGENCY: Assistant Secretary of Defense Officer, Department of Defense. (Health Affairs), DoD. Meeting will be held at the Naval Heritage Center, 701 Pennsylvania [FR Doc. 2015–05205 Filed 3–5–15; 8:45 am] ACTION: Notice of meeting. Avenue NW., Washington, DC 20004. BILLING CODE 5001–06–P VerDate Sep<11>2014 18:59 Mar 05, 2015 Jkt 235001 PO 00000 Frm 00021 Fmt 4703 Sfmt 9990 E:\FR\FM\06MRN1.SGM 06MRN1


Document Created: 2018-02-21 09:33:06
Document Modified: 2018-02-21 09:33:06
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice of meeting.
DatesThursday, March 26, 2015, from 9 a.m. to 1 p.m.
ContactMr. William H. Blanche, Alternate DFO, Uniform Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042-5101. Telephone: (703) 681-2890.
FR Citation80 FR 12158 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR